Endotoxin Challenge Study For Healthy Men and Women

A Double Blind, Placebo Controlled, Repeat Dose Study to Compare the Effectiveness of Two Doses of GSK256066 With Placebo in Reducing Lung Inflammation Following Segmental LPS Challenge in Healthy Volunteers

The proposed study will examine the effect of pre-treatment with inhaled GSK256066 using a lung inflammation model induced by bronchoscopic instillation of bacterial endotoxin (lipopolysaccharide, LPS) in healthy volunteers.Data from this study will be used to support GSK256066 dose selection for future studies in COPD patients.

Inclusion Criteria:

• Healthy males and females (contraception restrictions),
• 18-50yrs,
• BMI 19-31kg/m2,
• Non-smokers,
• FEV1 >/= 80% predicted

Exclusion Criteria:

• Abnormal troponin and/or CK MB,
• Participated in any GSK study involving the administration of COA for >/= 21 days.